titan medic inc tmdi hold due financ issu uncertain develop timelin withdraw guidanc
downgrad share hold analyst anthoni vendetti full summari
dolphin entertain inc dlpn buy pt expect initi fuel acceler growth profit
maintain buy lower pt analyst vander aard full summari
 buy pt record loan origin effici rais estim price
reiter buy analyst michael diana full summari
azurrx biopharma inc azrx buy pt dose initi phase sever patient new ceo come board
inc buy pt maintain buy pt capit expenditur growth
meaning chang competit landscap analyst tate sullivan cfa full summari
space heat elev move toward data analyst jason mccarthi ph full summari
corpor event call maxim salesperson inform
horizon technolog financ corp hrzn cover diana ndr boston ceo rob pomeroy cfo
volitionrx limit vnrx cover mccarthi ndr dalla ceo cameron reynold tue oct
contrafect corp cfrx cover mccarthi ndr nyc ceo roger pomerantz cfo michael messing
dynatron corpor dynt cover vendetti ndr nyc ceo brian baker vice-president corpor
california restaur tour habt host mon-tu
cover sullivan ndr philadelphia ceo batrack mon-tu dec
cover sullivan ndr baltimor ceo batrack tue-w dec
graham corpor cover sullivan ndr st loui cfo jeffrey glajch thu dec
graham corpor cover sullivan ndr kansa citi cfo jeffrey glajch fri dec
cover chokshi ndr philadelphia ceo jeff rosica fri
pure storag inc cover chokshi ndr san francisco presid dave hatfield tue dec
record loan origin effici
rais estim price target reiter buy
result includ record loan origin lower effici ratio spite
reduc wealth manag fee due departur advisor
group continu excel credit qualiti nim linked-
quarter manag guid addit nim compress
expect stabl nim
rais ep estim base
new ep estim rais price target new
price target equat unchang new ep estim
in-line best-in-class smid-cap bank
report ep versu consensu estim
beat driven record loan origin result strong linked-quart
loan growth manag indic loan pipelin remain strong
also good quarter loan growth net interest margin nim
loan yield fell faster fund rate manag guid
anoth nim compress expect stabl nim
core effici ratio versu due strong net interest
incom restrain expens expens guidanc reduc low-
double-digit low-teen
datacredit qualiti excel regard credit qualiti
excel non-performing asset loan
net charge-off averag loan provis loan loss
averag loan due loan growth
synergist busi model combin privat bank busi bank
wealth manag view three compon synergist produc
core deposit regard best indic franchis valu main
busi bank client non-profit ventur capit firm non-profit keep
core deposit compani typic use wealth manag servic
ventur capit firm borrow capital-cal line addit board member
execut non-profit partner vc firm excel candid
privat bank includ mortgag wealth manag board
member excel candid busi bank also growth-
orient view
rais ep estim mainli base higher
averag earn asset lower effici ratio page updat
rais price target base new ep estim
share current trade new ep estim new price
target equat unchang new ep estim in-line best-
reiter buy rate next four quarter expect stock price
appreci price target dividend yield
result estim total return
click full note
due financ issu uncertain develop
timelin withdraw guidanc downgrad share
hold
yesterday market close titan medic announc file
amend restat preliminari prospectu titan propos rais
market offer
titan medic also withdraw previous publish mileston
respect cost time develop robot surgic
system beyond addit compani relationship servic
provid deterior result su unpaid
base inform restat preliminari prospectu
concern regard uncertainti tmdi product develop mileston
downgrad share hold buy remov prior
price target
bottom line yesterday market close titan medic issu press releas
file amend restat preliminari prospectus connect
propos market offer total gross proce addit titan
medic announc withdraw forward-look statement respect
cost time develop robot surgic system beyond
guidanc withdraw due lack financ caus primari product
develop supplier limit work compani robot surgic system
opinion although compani current attempt rais capit believ
withdraw guidanc creat uncertain futur therefor downgrad
share hold buy remov prior price target
propos offer titan medic current process attempt rais
fund offer unit unit compris one common share
one common share purchas warrant compani expect close
offer occur octob anticip total gross proce
minimum maximum net proce use
fund continu develop work connect compani single-port robot
surgic system well work capit gener purpos
mileston withdraw titan medic also announc withdraw forward-
look statement includ continu disclosur document respect
cost time develop robot surgic system beyond
includ estim cost mileston date withdraw due lack
financ caus titan primari product develop limit develop work
titan robot surgic system supplier termin employ
engag signific number employe work titan
single-port robot surgic system addit tmdi relationship deterior
servic provid servic provid note concern titan
inabl pay full invoic price titan express dissatisfact
qualiti servic provid work octob compani receiv letter
attorney servic provid demand payment octob
titan issu respons letter declin demand octob
letter believ feud compani servic provid may significantli
hamper abil continu develop main product also opinion addit
time cost may requir resum work robot surgic system
click full note
expect initi fuel acceler growth
profit maintain buy lower pt
believ dlpn well-posit profit growth addit
viewpoint promot video door new consum divis
expect movi product provid second leg growth start
potenti
maintain estim highlight includ project revenu
growth entertain public contribut
product distribut
anticip dlpn like continu make acquisit build
super group entertain public present potenti upsid
revenu outlook
dlpn trade revenu estim estim
unchang lower pt repres
revenu in-line peer group
believ dlpn well-posit growth driven ramp contribut
cross-sel opportun recent acquir busi highlight
dlpn revenu estim
consensu estim driven strong contribut viewpoint
acquir novemb acquir juli consid
revenu beat especi impress given lack industri award event
host month april may june histor result
season low period suggest dlpn subsidiari busi
gain momentum dlpn build new consum divis part
busi anticip drive increment revenu dlpn move
launch new offic miami florida believ like ahead
manag initi expans plan consid announc posit
indic dolphin confid growth outlook manag
also highlight opportun cross-sel revenu opportun among
divis includ highli profit promot video creat viewpoint
believ compani like continu make acquisit build super
group entertain public next month
preview result result expect releas mid-
novemb estim revenu flat y/i consist entir entertain
public segment revenu slightli consensu estim
one three analyst cover stock also estim adjust
ebitda loss compar consensu estim
anticip revenu growth begin acceler reach
y/i slightli consensu estim
project growth entertain public
contribut product distribut continu view
invest year compani build super group new servic
project revenu increas y/i consensu estim
entertain public repres nearli total revenu mix
manag target first film produc later project
initi film product revenu begin estim first film contribut
total revenu expect revenu increas y/i
in-lin consensu larg driven increment contribut
product distribut segment expect contribut
revenu compar estim project adjust ebitda
loss given acceler pace dlpn abil acquir new talent
slightli wider consensu estim loss project
posit adjust ebitda result everi quarter drive adjust
ebitda vs consensu estim posit correspond
adjust ebitda margin
reduc price target use revenu multipl
in-line peer group maintain buy rate stock current trade
revenu estim respect new price
target base revenu estim
correspond ep estim revenu multipl target
in-line peer group still repres signific upsid buy
rate reflect expect deliv acceler top-line growth
first full year profit cash flow gener divis
anticip ramp contribut compani content product busi
compani descript dolphin entertain lead independ entertain
market premium content develop compani entertain public
market along content product entertain pr firm
acquir march provid strateg market public servic
major film studio mani digit content provid addit hundr
a-list celebr includ actor artist produc director athlet author
addit entertain public divis includ lead lifestyl
hospit public relat creativ brand market servic agenc
acquir juli viewpoint creativ full servic creativ brand
product agenc acquir novemb
click full note
nmda space heat elev move
note relmada therapeut rlmd nr share trade
follow announc posit data compani drug
dextromethadon adjunct therapi major depress disord
sever point consid view valid
emerg nmda antidepress space bode well
vistagen await top-lin data elev studi
target adjunct therapi nmda induc posit effect
difficult treat mdd relmada axsom nr nr
shown
effect nmda drugs- relmada drug improv madr score
day continu day recal avail
antidepress class take month work
side effect valu larg effect size
safety- safe well toler complet
treatment dose psychotomimet dissoci
compar favor axsom dextromethorphan/
bupropion trial data drove share significantli
higher share rlmd news albeit cross-
vistagen nmda antagonist select
partial vs full block well relmada axsom trial
outcom posit vistagen view elev studi
also much larger bottom line axsom relmada
shown rel small number patient mdd moder
nmda antagon rapid sustain safe effect depress
elev also go day vistagen replic success
space base success space moa prior data
like risk/reward see vtgn attract valuat rel
nmda-target pier
relamda data trial enrol patient mdd
respond cours antidepress current depress episod
averag age patient year averag hamilton depress rate
scale score averag montgomery-asberg depress rate scale
madr score sever depress patient random placebo
addit standard antidepress patient
treat in-pati day discharg day follow-up day
efficaci measur day dose period day
one week discontinu complet treatment complet
visit group experienc stat-sig improv
placebo measur includ madr score clinic global impression-sever
cgi- clinic global impression-improv cgi-i symptom depress
questionnair sdq improv madr score appear day
continu day week treatment discontinu valu
larg effect size rang cgi- cgi-o scale measur
compar safeti profil posit mild-mod
differ drug placebo group psycholog effect dissoci
observ
axsom data ascend studi data report januari
ascend studi random double-blind active-control multi-cent
 trial adult patient confirm moder sever mdd
treat either mg mg bupropion activ
compar bupropion mg twice daili week ascend studi
random double-blind active-control multi-cent trial adult
patient confirm moder sever mdd treat either
mg mg bupropion activ compar bupropion
mg twice daili week associ statist signific mean
reduct baselin montgomery-sberg depress rate scale madr
total score calcul time point studi averag point
compar bupropion week associ
statist signific mean reduct baselin madr total score
point compar reduct point bupropion remiss
absenc clinic signific symptom depress prospect defin
madr total score seen week patient receiv
compar patient receiv bupropion
relamda studi import consid time see treatment effect
depress nmda-target drug ascend studi reach stat-
sig madr score baselin first two week vs bupropion
numer differ week well unlik relmada studi
observ effect day effect sustain evidenc
reduct week point compar reduct point
bupropion remiss rate statist significantli superior
compar bupropion start week everi time point
thereaft includ week measur around cgi-i track chang
madr week one effect continu week though bare
miss stat-sig valu week one safeti profil
elev studi data studi evalu adjunct
fda-approv antidepress patient mdd inadequ respons
soc trial multi-cent random double-blind placebo-control
design use sequenti parallel comparison design spcd order
minim placebo respons gener cohort placebo non-respond
random patient trial approach increasingli common
studi trial evalu oral dose day
day patient studi also take regular antidepress
regimen primari endpoint efficaci measur decreas
montgomery-asberg depress rate scale version two
week secondari endpoint includ safeti toler measur sae
depress measur time improv scale
last patient complet dose data expect end
click full note
dose initi phase sever patient new ceo
azurrx announc initi dose combin studi
porcin enzym replac therapi pert cystic fibrosi
cf patient sever exocrin pancreat insuffici epi
new ceo board posit view jame sapirstein bring extens
year experi pharma/biotech rang drug develop
combo studi trial target enrol patient sever epi
repres cf patient patient mani achiev
suffici fat absorpt cfa despit take maximum daili dose
pert therapi iu lipase/kg/day data trial expect
addit compani meet fda discuss next step
moder epi recal posit signal prior
option studi low dose expect second studi
higher dose
combin studi sever epi first patient dose
phase combin studi pert trial target enrol
patient sever case cf-relat epi cf patient alreadi
maximum dose pert iu lipase/kg/day still experi fat
malabsorpt cfa malnutrit trial design dose escal
studi day screen day establish baselin patient
receiv dose day mg/day
mg/day end trial day follow-up primari
endpoint includ safeti coeffici fat absorpt cfa preliminari data
expect earli
address wider cf epi popul azurrx evalu two differ
dose regimen address broad section cf-relat epi patient
monotherapi moder epi pert sever epi
combin therapi target sever epi sever case cf-relat
epi patient patient diseas often adequ treat despit
maximum dose pert iu lipase/kg/day even specialist cf
center patient experi fat malabsorpt cfa anoth
cfa lead malnutrit particularli
concern cf patient direct correl malnutrit
pulmonari function often patient also requir gastric tube receiv adequ
nutrit unpleas treatment deliv food skin
stomach one reason upper limit pert risk fibros
colonopathi though limit measur lipas dose condit
like caus inflamm due proteas present similar proport
synthet lipas enrich pert regimen addit lipas
necessari fat absorpt without trigger inflammatori respons
monotherapi target moder epi monotherapi target cf
patient moder diseas patient respond pert high pill
burden requir mani pill day could potenti replac pert
pill day prior studi moder epi trial meet
primari endpoint efficaci per se import note trial
trial meant inform next step said key aspect
focu one low dose evalu per trial design assess
safeti go higher dose nonetheless even lower gram dose
got patient non-inferior pert therapi proteas need
signific posit well demonstr compar coeffici
nitrogen absorpt vs valid rational gut bacteri
proteas enough deal break protein cfa data cf trial
rel consist cfa data chronic pancreat trial import latter
patient underw washout pert therapi prior thu
clear demonstr therapeut effect note
inform path forward signal efficaci
posit safeti suggest data could improv higher dose benchmark
non-inferior point pert fda meet decemb
expect anoth trial earli evalu higher dose pave path forward
registr studi
click full note
maintain buy pt capit expenditur
growth meaning chang competit
report quarterli earn thursday pre-market open
increas ep forecast last month
maintain buy rate base outlook growth
water util capit expenditur futur dividend increas greater
annual margin growth on-going custom adopt new water
believ short interest increas share outstand
septemb base specul mention short-
term innov delay thursday earn report confer call
similar compani last earn report
slightli decreas revenu forecast
take account risk order delay water meter kit
includ lte-m radio maintain ep forecast base
higher margin forecast lower copper price product mix
revenu forecast consensu ep
consensu
separ continu believ oper oligopoli market
 water meter market much larger compani roper
rate rate
oppos previou quarter above-consensu ep estim
forecast report ep thursday pre-market
open consensu revenu anticip y/i growth
y/i declin prior quarter due deliveri delay mention
last quarter lte-m radio client test lower manufactur
cost even deliveri delay believ maintain
gross profit margin previou quarter due lower cost
put lte-m radio new meter also note last year employ current
ceo kenneth bockhorst previou ceo richard meeusen mr meeusen
retir decemb last copper price make mold mani
meter decreas y/i accord bloomberg summari believ
cost margin consider allow ep increas modestli y/i
oper ep prior year
comment last confer call observ meaning
chang competit believ current account
instal water meter much larger compani
variou product line compani smaller current market
share water meter market continu compet aggress order
continu believ focu meter histori custom
maintain buy rate price target share current trade pe
multipl ep estim price target base
ep estim appli premium multipl pe
multipl multipl base concentr exposur
water meter market sell type equip servic
click full note
maxim analyst coverag univers
